Back
Bicycle Therapeutics PLC 10K Form
Sell
2
BCYC
Bicycle Therapeutics PLC
Last Price:
$14.70
Seasonality Move:
10.25%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2020-11-05 | 10Q | BCYC/Bicycle Therapeutics PLC Quarterly |
| 2020-08-05 | 10Q | BCYC/Bicycle Therapeutics PLC Quarterly |
| 2020-05-07 | 10Q | BCYC/Bicycle Therapeutics PLC Quarterly |
| 2020-03-10 | 10K | BCYC/Bicycle Therapeutics PLC Annual |
| 2019-11-07 | 10Q | BCYC/Bicycle Therapeutics PLC Quarterly |
| 2019-08-08 | 10Q | BCYC/Bicycle Therapeutics PLC Quarterly |
Receive BCYC News And Ratings
See the #1 stock for the next 7 days that we like better than BCYC
BCYC Financial Statistics
Sales & Book Value
| Annual Sales: | $27M |
|---|---|
| Cash Flow: | $-40.3M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $12.04 |
| Price / Book: | 1.22 |
Profitability
| EPS (TTM): | -3.29000 |
|---|---|
| Net Income (TTM): | $-166.3M |
| Gross Margin: | -- |
| Return on Equity: | -29.19% |
| Return on Assets: | -21.68% |
Bicycle Therapeutics PLC Earnings Forecast
Key Bicycle Therapeutics PLC Financial Ratios
-
The Research & Development expenses have been 580.13% of Revenue.
-
The Interest Expense is -1.81% of Operating Income.
-
The Net Earning history of BCYC is -669.72% of Total Revenues.
-
Per Share Earnings over the last 7 years have been positive in 1 years.
Bicycle Therapeutics PLC Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | BCYC |
| CUSIP: | 088786 |
| Website: | bicycletherapeutics.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 17.13 |
| Quick Ratio: | 16.82 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
BCYC Technical Analysis vs Fundamental Analysis
Sell
2
Bicycle Therapeutics PLC (BCYC)
is a Sell
Is Bicycle Therapeutics PLC a Buy or a Sell?
-
Bicycle Therapeutics PLC stock is rated a SellThe current Bicycle Therapeutics PLC [BCYC] share price is $14.68. The Score for BCYC is 2, which is 96% below its historic median score of 50, and infers higher risk than normal.